Patents by Inventor Victor J. Torres

Victor J. Torres has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cellular factors involved in the cytotoxicity of leukocidins: novel therapeutic targets
    Patent number: 11932683
    Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
    Type: Grant
    Filed: September 14, 2022
    Date of Patent: March 19, 2024
    Assignee: NEW YORK UNIVERSITY
    Inventors: Victor J. Torres, Tamara Reyes-Robles, Francis Alonzo
  • VARIANT STAPHYLOCOCCUS AUREUS LUKA AND LUKB POLYPEPTIDES AND VACCINE COMPOSITIONS
    Publication number: 20240050546
    Abstract: The present disclosure relates to Staphylococcus aureus leukocidin A (LukA) and leukocidin B (LukB) variant polypeptides, and polynucleotides encoding the LukA, LukB and LukAB variant polypeptides. The present disclosure further relates to vaccine compositions comprising these LukA and LukB variants, and methods of generating an immune response against Staphylococcus aureus in a subject.
    Type: Application
    Filed: September 28, 2021
    Publication date: February 15, 2024
    Inventors: Brian MORROW, Sergey KONSTANTINOV, Jeroen GEURTSEN, Jinquan LUO, Sandeep SOMANI, Peter T. BUCKLEY, Victor J. TORRES
  • STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF
    Publication number: 20230295248
    Abstract: Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
    Type: Application
    Filed: January 12, 2023
    Publication date: September 21, 2023
    Inventors: Victor J. TORRES, Ashley L. DUMONT
  • CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS
    Publication number: 20230151081
    Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
    Type: Application
    Filed: September 14, 2022
    Publication date: May 18, 2023
    Inventors: Victor J. TORRES, Tamara REYES-ROBLES, Francis ALONZO
  • leukocidins, therapeutic compositions, and uses thereof
    Patent number: 11584782
    Abstract: Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: February 21, 2023
    Assignee: NEW YORK UNIVERSITY
    Inventors: Victor J. Torres, Ashley L. Dumont
  • Cellular factors involved in the cytotoxicity of leukocidins: novel therapeutic targets
    Patent number: 11453715
    Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: September 27, 2022
    Assignee: NEW YORK UNIVERSITY
    Inventors: Victor J. Torres, Tamara Reyes-Robles, Francis Alonzo, III
  • METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS
    Publication number: 20210340228
    Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.
    Type: Application
    Filed: July 6, 2021
    Publication date: November 4, 2021
    Inventors: Victor J. TORRES, Francis ALONZO, III
  • Compositions and methods for antibodies targeting staphylococcal leukotoxins
    Patent number: 11104724
    Abstract: The disclosure is directed to antibodies that bind to Staphylococcus aureus bi-component leukotoxins and/or gamma-hemolysins. Other aspects of the disclosure are directed to pharmaceutical compositions and diagnostic kits containing the leukotoxin and hemolysin antibodies, and therapeutic and diagnostic methods utilizing the leukotoxin and hemolysin antibodies.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: August 31, 2021
    Assignees: NEW YORK UNIVERSITY, JANSSEN BIOTECH, INC.
    Inventors: Victor J. Torres, Anthony S. Lynch, Peter T. Buckley, Nathan Majewski
  • Methods of treating and preventing infections and associated conditions
    Patent number: 11078258
    Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: August 3, 2021
    Assignee: NEW YORK UNIVERSITY
    Inventors: Victor J. Torres, Francis Alonzo, III
  • CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS
    Publication number: 20210009664
    Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
    Type: Application
    Filed: June 5, 2020
    Publication date: January 14, 2021
    Inventors: Victor J. TORRES, Tamara REYES-ROBLES, Francis ALONZO, III
  • METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS
    Publication number: 20200392211
    Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.
    Type: Application
    Filed: April 28, 2020
    Publication date: December 17, 2020
    Inventors: Victor J. TORRES, Francis ALONZO, III
  • COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING STAPHYLOCOCCAL LEUKOTOXINS
    Publication number: 20200317758
    Abstract: The disclosure is directed to antibodies that bind to Staphylococcus aureus bi-component leukotoxins and/or gamma-hemolysins. Other aspects of the disclosure are directed to pharmaceutical compositions and diagnostic kits containing the leukotoxin and hemolysin antibodies, and therapeutic and diagnostic methods utilizing the leukotoxin and hemolysin antibodies.
    Type: Application
    Filed: May 23, 2017
    Publication date: October 8, 2020
    Inventors: Victor J. TORRES, Anthony S. LYNCH, Peter T. BUCKLEY, Nathan MAJEWSKI
  • Compositions and methods for anti-staphylococcal biologic agents
    Patent number: 10781246
    Abstract: The present disclosure is directed to staphylococcal leukotoxin and hemolysin binding molecules and fusion constructs. The present disclosure is further directed to methods of treating, preventing, and diagnosing staphylococcal infection in a subject using the binding molecules and fusion constructs described herein.
    Type: Grant
    Filed: June 4, 2016
    Date of Patent: September 22, 2020
    Assignees: NEW YORK UNIVERSITY, JANSSEN BIOTECH, INC.
    Inventors: Randall J. Brezski, Anthony S. Lynch, Peter T. Buckley, Jeffrey Fernandez, Jinquan Luo, Thomas J. Malia, Sheng-Jiun Wu, Victor J. Torres
  • Methods of treating and preventing infections and associated conditions
    Patent number: 10669329
    Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: June 2, 2020
    Assignee: New York University
    Inventors: Victor J. Torres, Francis Alonzo, III
  • STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF
    Publication number: 20190330284
    Abstract: Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
    Type: Application
    Filed: May 6, 2019
    Publication date: October 31, 2019
    Inventors: Victor J. TORRES, Ashley L. DUMONT
  • CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS
    Publication number: 20190248876
    Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Inventors: Victor J. TORRES, Tamara REYES-ROBLES, Francis ALONZO, III
  • leukocidins, therapeutic compositions, and uses thereof
    Patent number: 10316067
    Abstract: Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: June 11, 2019
    Assignee: New York University
    Inventors: Victor J. Torres, Ashley L. Dumont
  • Cellular factors involved in the cytotoxicity of leukocidins: novel therapeutic targets
    Patent number: 10301378
    Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: May 28, 2019
    Assignee: New York University
    Inventors: Victor J. Torres, Tamara Reyes-Robles, Francis Alonzo, III
  • METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS
    Publication number: 20190135900
    Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 9, 2019
    Inventors: Victor J. TORRES, Francis ALONZO, III
  • COMPOSITIONS AND METHODS FOR ANTI-STAPHYLOCOCCAL BIOLOGIC AGENTS
    Publication number: 20190127444
    Abstract: The present disclosure is directed to staphylococcal leukotoxin and hemolysin binding molecules and fusion constructs. The present disclosure is further directed to methods of treating, preventing, and diagnosing staphylococcal infection in a subject using the binding molecules and fusion constructs described herein.
    Type: Application
    Filed: June 4, 2016
    Publication date: May 2, 2019
    Inventors: Randall J. BREZSKI, Anthony S. LYNCH, Peter T. BUCKLEY, Jeffrey FERNANDEZ, Jinquan LUO, Thomas J. MALIA, Sheng-Jiun WU, Victor J. TORRES